AI assistant
Sending…
Lexeo Therapeutics, Inc. — Director's Dealing 2025
Feb 21, 2025
33133_dirs_2025-02-21_ff6b4a95-475e-44c3-949a-3a9ceb887963.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexeo Therapeutics, Inc. (LXEO)
CIK: 0001907108
Period of Report: 2025-02-19
Reporting Person: Townsend Richard Nolan (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-19 | Common Stock | S | 4326 | $4.413 | Disposed | 220119 | Direct |
Footnotes
F1: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F2: Includes 136,562 RSUs.
More from Lexeo Therapeutics, Inc.
Interim / Quarterly Report
2026
May 11
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Regulatory Filings
2026
Apr 30
Annual Report
2026
Mar 30
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Feb 20
Director's Dealing
2026
Feb 20